Clinical trials: Post Herpetic Pain
Neuralgia, Postherpetic
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
- Trial name
- NCT00619476
- Testing
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day
- Where
- 83 sites in United States, Canada
- Volunteers
- 376 people
- Sponsor
- XenoPort, Inc.
Post Herpetic Neuralgia
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
- Trial name
- NCT01270828
- Testing
- Pregabalin
- Where
- 146 sites in United States, Bulgaria and 15 more
- Volunteers
- 806 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Neuralgia, Postherpetic
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.
- Trial name
- NCT00617461
- Testing
- GEn 1200mg/day, GEn 3600mg/day
- Where
- 53 sites in United States, Germany
- Volunteers
- 96 people
- Sponsor
- XenoPort, Inc.
Post-Herpetic Neuralgia
DS-5565 Phase III Study for Post-herpetic Neuralgia
Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo
- Trial name
- NCT02318719
- Testing
- DS-5565
- Where
- Japan
- Volunteers
- 765 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Postherpetic Neuralgia
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
The purpose of the study is to evaluate the efficacy of retigabine vs. placebo in reducing pain associated with post-herpetic neuralgia.
- Trial name
- NCT00612105
- Testing
- Retigabine
- Where
- 45 sites in United States, South Africa
- Volunteers
- 187 people
- Sponsor
- Bausch Health Americas, Inc.
Postherpetic Neuralgia
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with post-herpetic neuralgia.
- Trial name
- NCT00981227
- Testing
- Eslicarbazepine acetate
- Volunteers
- 567 people
- Sponsor
- Bial - Portela C S.A.
Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN)
Oral LAT8881 in Neuropathic Pain
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
- Conditions
- Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN)
- Trial name
- NCT03865953
- Testing
- LAT8881
- Where
- 6 sites in Australia, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Lateral Pharma Pty Ltd
Post Herpetic Neuralgia, PHN
A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
The purpose of this study is to compare EpiCept™ NP-1 Topical Cream (2% ketamine / 4% amitriptyline) vs. Oral Gabapentin in the treatment of Postherpetic Neuralgia (PHN)
- Conditions
- Post Herpetic Neuralgia, PHN, Neuropathy, Nerve Pain
- Trial name
- NCT00475904
- Testing
- EpiCept-NP-1 Cream, Gabapentin Capsules
- Where
- India
- Volunteers
- 360 people
- Sponsor
- EpiCept Corporation
Postherpetic Neuralgia
The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia.
- Trial name
- NCT02336555
- Testing
- MK-8291
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Postherpetic Neuralgia
A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug.
- Trial name
- NCT00599638
- Testing
- pregabalin, pregabalin/PF-00489791
- Where
- 39 sites in United States
- Volunteers
- 72 people
- Sponsor
- Pfizer
Neuralgia
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
The purpose of this study is to evaluate the safety, tolerability and continued efficacy of perampanel in patients previously enrolled in double-blind, placebo-controlled studies for Painful Diabetic Neuropathy (PDN) or…
- Trial name
- NCT00592904
- Testing
- E2007
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Eisai Inc.
Diabetic Peripheral Neuropathic Pain, Post-herpetic Neuralgia
DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
Investigate the safety and efficacy of DS-5565 in Japanese subjects with Diabetic Peripheral Neuropathic Pain (DPNP) with renal impairment or Post-Herpetic Neuralgia (PHN) with renal impairment.
- Trial name
- NCT02607280
- Testing
- DS-5565
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Neuralgia
Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
The purpose of the study is to determine the efficacy and safety of Perampanel (E2007) in patients with Post-Herpetic Neuralgia (PHN).
- Trial name
- NCT00592774
- Testing
- E2007 (perampanel)
- Where
- 47 sites in United States, Canada
- Volunteers
- 146 people
- Sponsor
- Eisai Inc.
Pain
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
- Trial name
- NCT00415597
- Testing
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- Where
- 58 sites in United States
- Volunteers
- 467 people
- Sponsor
- Pfizer
Neuralgia, Postherpetic
RN624 For Pain Of Post-Herpetic Neuralgia
This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
- Trial name
- NCT00568321
- Testing
- RN624
- Where
- 31 sites in United States
- Volunteers
- 99 people
- Sponsor
- Pfizer
Postherpetic Neuralgia, Complex Regional Pain Syndromes (CRPS)
A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome
The purpose of this study is to evaluate the efficacy and safety of fentanyl in opioid-naive participants with post-herpetic neuralgia, complex regional pain syndrome or post-operative pain syndrome who cannot obtain a sufficient…
- Conditions
- Postherpetic Neuralgia, Complex Regional Pain Syndromes (CRPS), Postoperative Pain
- Trial name
- NCT01008553
- Testing
- Fentanyl
- Where
- 79 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Janssen Pharmaceutical K.K.
Post Herpetic Neuralgia
Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia
The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Post-herpetic Neuralgia (PHN) over a 15 week treatment phase.
- Trial name
- NCT01124097
- Testing
- Eslicarbazepine acetate (BIA 2-093)
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- Bial - Portela C S.A.
Herpes Zoster
Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
The purpose of this study is to assess the burden of Herpes zoster (HZ) and post-herpetic neuralgia (PHN) among people ≥ 50 years old in France, in terms of healthcare resources used, medical direct and indirect costs, as well as…
- Trial name
- NCT02487472
- Testing
- Data collection
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Post-herpetic Neuralgia
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
This study was designed to characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN).
- Trial name
- EMPHENE (NCT03094195)
- Testing
- EMA401
- Where
- 58 sites in Australia, Austria and 17 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Post Herpetic Neuralgia
Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice
- Trial name
- NCT01426230
- Where
- 37 sites in United States
- Volunteers
- 201 people
- Sponsor
- Depomed